Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons-Reference-Cited by-同舟云学术

Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons

Published:2023-02 Issue:2 Volume:78 Page:442-447
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Pericàs Juan M.,Tacke Frank^ORCID,Anstee Quentin M.^ORCID,Di Prospero Nicholas A.,Kjær Mette Skalshøj,Mesenbrink Peter^ORCID,Koenig Franz,Genescà Joan^ORCID,Ratziu Vlad

Funder

European Commission

Horizon 2020 Framework Programme

Innovative Medicines Initiative

European Federation of Pharmaceutical Industries and Associations

Children's Tumor Foundation

Springworks Therapeutics

Publisher

Elsevier BV

Subject

Hepatology

Reference33 articles.

1. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis;Younossi;Hepatology,2019

2. Pathogenesis of nonalcoholic steatohepatitis;Liu;Cell Mol Life Sci,2016

3. Breakthroughs in therapies for NASH and remaining challenges;Ratziu;J Hepatol,2022

4. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis;Vilar-Gomez;Gastroenterology,2015

5. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis;Promrat;Hepatology,2010

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A roadmap for clinical trials in MASH-related compensated cirrhosis;Nature Reviews Gastroenterology & Hepatology;2024-07-17

2. Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis;Communications Medicine;2024-07-16

3. Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?;Expert Opinion on Pharmacotherapy;2024-06-12

4. Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases;Neuro-Oncology Practice;2024-01-04

5. Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL;eClinicalMedicine;2024-01